Note: Syros Pharmaceuticals's revenues are gauged from an analysis of company filings.
Syros Pharmaceuticals has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
February 9, 2018
Complete list of funding rounds and total amounts in the Company Report
Syros Pharmaceuticals's Income Statement (based on Industry Averages)
$ Millions (Industry Average)
Syros Pharmaceuticals Revenue (Sales)
Cost of Goods Sold
Salaries and wages
Other Operating Expenses
Total Operating Expenses
EBIT (Earnings Before Interest and Taxes)
Trademark applications show the products and services that Syros Pharmaceuticals is developing and marketing.
Syros Pharmaceuticals doesn't have any recent trademark applications, indicating Syros Pharmaceuticals is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
SYROS pharmaceutical preparations and compounds for use in the treatment of cancer; pharmaceutical preparations and compounds for inhibition of transcriptional regulators
SYROS PHARMACEUTICALS pharmaceutical preparations and compounds for use in the treatment of cancer; pharmaceutical preparations and compounds for inhibition of transcriptional regulators
Determine whether Syros Pharmaceuticals grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Syros Pharmaceuticals is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
These companies are similar in business line and location to Syros Pharmaceuticals.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Syros Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.